Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Total Liabilities: 2017-2024

Historic Total Liabilities for Protagonist Therapeutics (PTGX) over the last 8 years, with Dec 2024 value amounting to $69.4 million.

  • Protagonist Therapeutics' Total Liabilities fell 21.81% to $56.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.3 million, marking a year-over-year decrease of 21.81%. This contributed to the annual value of $69.4 million for FY2024, which is 226.36% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Total Liabilities stood at $69.4 million for FY2024, which was up 226.36% from $21.3 million recorded in FY2023.
  • Protagonist Therapeutics' 5-year Total Liabilities high stood at $69.4 million for FY2024, and its period low was $21.3 million during FY2023.
  • Its 3-year average for Total Liabilities is $41.0 million, with a median of $32.3 million in 2022.
  • Its Total Liabilities has fluctuated over the past 5 years, first tumbled by 40.15% in 2020, then spiked by 226.36% in 2024.
  • Protagonist Therapeutics' Total Liabilities (Yearly) stood at $44.9 million in 2020, then increased by 6.27% to $47.7 million in 2021, then crashed by 32.21% to $32.3 million in 2022, then slumped by 34.18% to $21.3 million in 2023, then surged by 226.36% to $69.4 million in 2024.